Less Is More? Understanding and Rewarding the Full Value of Long-Acting Therapies

ISSUE: Long-acting (LA) therapies have the potential to transform treatment paradigms for various chronic conditions. However, current health technology assessment (HTA) frameworks struggle to fully capture their broader impacts, such as benefits to healthcare capacity, productivity, impact on carers, supply chain stability, and environmental sustainability. These limitations may affect patient access, product uptake, health system sustainability, and pharmaceutical innovation. OVERVIEW: This Issue Panel will explore the methodological, evidentiary, pricing and reimbursement challenges of LA therapies affecting current HTA and payer decisions, as well as the implications for patients, healthcare systems, and society. The debate aims to identify practical strategies to better align HTA and reimbursement frameworks with the transformative potential of LA therapies, fostering more comprehensive, sustainable and equitable decision-making. The moderator will introduce topic by providing a brief overview of challenges in valuing LAtherapies and sharing examples of current practices in North America and Europe (6 mins). Each panellist will then provide their perspective in about 8 mins each. Interactive audience engagement (incl. polling) will be done throughut the session (5 min). The session wil conclude with audience Q&A (25 min).